Sacha Gnjatic to Female
This is a "connection" page, showing publications Sacha Gnjatic has written about Female.
Connection Strength
0.058
-
An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med. 2020 10; 26(10):1636-1643.
Score: 0.012
-
NY-ESO-1: review of an immunogenic tumor antigen. Adv Cancer Res. 2006; 95:1-30.
Score: 0.004
-
Downregulation of exhausted cytotoxic T cells in gene expression networks of multisystem inflammatory syndrome in children. Nat Commun. 2021 08 11; 12(1):4854.
Score: 0.003
-
Serologic Response to Messenger RNA Coronavirus Disease 2019 Vaccines in Inflammatory Bowel Disease Patients Receiving Biologic Therapies. Gastroenterology. 2021 08; 161(2):715-718.e4.
Score: 0.003
-
Pathophysiology of SARS-CoV-2: the Mount Sinai COVID-19 autopsy experience. Mod Pathol. 2021 08; 34(8):1456-1467.
Score: 0.003
-
Intestinal Host Response to SARS-CoV-2 Infection and COVID-19 Outcomes in Patients With Gastrointestinal Symptoms. Gastroenterology. 2021 06; 160(7):2435-2450.e34.
Score: 0.003
-
A streamlined whole blood CyTOF workflow defines a circulating immune cell signature of COVID-19. Cytometry A. 2021 05; 99(5):446-461.
Score: 0.003
-
Mapping Systemic Inflammation and Antibody Responses in Multisystem Inflammatory Syndrome in Children (MIS-C). Cell. 2020 11 12; 183(4):982-995.e14.
Score: 0.003
-
A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward. J Hematol Oncol. 2020 07 14; 13(1):94.
Score: 0.003
-
First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1. Clin Cancer Res. 2019 10 01; 25(19):5808-5817.
Score: 0.003
-
First-in-human phase 1 dose-escalating trial of G305 in patients with advanced solid tumors expressing NY-ESO-1. Cancer Immunol Immunother. 2019 Jul; 68(7):1211-1222.
Score: 0.003
-
Radiotherapy induces responses of lung cancer to CTLA-4 blockade. Nat Med. 2018 12; 24(12):1845-1851.
Score: 0.003
-
Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes. Eur Urol. 2018 05; 73(5):751-759.
Score: 0.002
-
First-in-Human Treatment With a Dendritic Cell-targeting Lentiviral Vector-expressing NY-ESO-1, LV305, Induces Deep, Durable Response in Refractory Metastatic Synovial Sarcoma Patient. J Immunother. 2017 10; 40(8):302-306.
Score: 0.002
-
Quantification of hepatocellular carcinoma heterogeneity with multiparametric magnetic resonance imaging. Sci Rep. 2017 05 26; 7(1):2452.
Score: 0.002
-
NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer. Gynecol Oncol. 2017 06; 145(3):420-425.
Score: 0.002
-
MAGE expression in head and neck squamous cell carcinoma primary tumors, lymph node metastases and respective recurrences-implications for immunotherapy. Oncotarget. 2017 Feb 28; 8(9):14719-14735.
Score: 0.002